Evidence map›Paper›PMID 36184192›Full record

ReviewBriefings in bioinformatics2022

High-dimensional genomic feature selection with the ordered stereotype logit model.

Anna Eames Seffernick, Krzysztof Mrózek, Deedra Nicolet, Richard M Stone, Ann-Kathrin Eisfeld, John C Byrd, Kellie J Archer

Abstract readReview
In one paragraph

Review in Briefings in bioinformatics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Anna Eames SeffernickDivision of Biostatistics, College of Public Health, The Ohio State University, Columbus, OH, USA.
Krzysztof MrózekClara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University, Columbus, OH, USA.
Deedra NicoletClara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University, Columbus, OH, USA.
Richard M StoneDana Farber/Partners Cancer Care, Harvard University, Boston, MA, USA.
Ann-Kathrin EisfeldClara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University, Columbus, OH, USA.
John C ByrdDepartment of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA.
Kellie J ArcherDivision of Biostatistics, College of Public Health, The Ohio State University, Columbus, OH, USA.

Funding

Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3M
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
Statistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0M
THE ALLIANCE NCTN BIOREPOSITORY AND BIOSPECIMEN RESOURCEU24CA196171 · NCI · WASHINGTON UNIVERSITY · PI Mine Cicek, Wendy Frankel · 2015 to 2026
$35.0M
OSU as a Network Lead Academic Participating Site for the NCI NCTNUG1CA233331 · NCI · OHIO STATE UNIVERSITY · PI John L. Hays, Dwight H. Owen · 2019 to 2026
$8.9M
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareUG1CA233180 · NCI · DANA-FARBER CANCER INST · PI Harold John Burstein · 2019 to 2026
$8.6M
Targeted Therapy for LeukemiaR35CA197734 · NCI · UNIVERSITY OF CINCINNATI · PI BYRD, JOHN C. · 2015 to 2021
$6.6M
ITSC for Leukemia: Novel Molecular strategies for NCTN "Individualized" TherapiesUG1CA233338 · NCI · UNIVERSITY OF CINCINNATI · PI BYRD, JOHN C. · 2019 to 2025
$4.5M
High-dimensional variable selection and prediction of ordinal pathological response dataR03CA245771 · NCI · OHIO STATE UNIVERSITY · PI ARCHER, KELLIE J. · 2020 to 2021
$148k
NCI NIH HHS P30 CA016058NCI NIH HHS R03 CA245771NCI NIH HHS R35 CA197734NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180882NCI NIH HHS U24 CA196171NCI NIH HHS UG1 CA233180NCI NIH HHS UG1 CA233331NCI NIH HHS UG1 CA233338
6 · The paper itself

Abstract

For many high-dimensional genomic and epigenomic datasets, the outcome of interest is ordinal. While these ordinal outcomes are often thought of as the observed cutpoints of some latent continuous variable, some ordinal outcomes are truly discrete and are comprised of the subjective combination of several factors. The nonlinear stereotype logistic model, which does not assume proportional odds, was developed for these 'assessed' ordinal variables. It has previously been extended to the frequentist high-dimensional feature selection setting, but the Bayesian framework provides some distinct advantages in terms of simultaneous uncertainty quantification and variable selection. Here, we review the stereotype model and Bayesian variable selection methods and demonstrate how to combine them to select genomic features associated with discrete ordinal outcomes. We compared the Bayesian and frequentist methods in terms of variable selection performance. We additionally applied the Bayesian stereotype method to an acute myeloid leukemia RNA-sequencing dataset to further demonstrate its variable selection abilities by identifying features associated with the European LeukemiaNet prognostic risk score.

Indexed as

GenomicsBayes TheoremLogistic ModelsRisk Factorsacute myeloid leukemiahierarchical modelordinal responsevariable selection

Identifiers

PMID36184192
PMCPMC9677495

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.